Acetylcholinesterase inhibitors: pharmacology and toxicology
- PMID: 24179466
- PMCID: PMC3648782
- DOI: 10.2174/1570159X11311030006
Acetylcholinesterase inhibitors: pharmacology and toxicology
Abstract
Acetylcholinesterase is involved in the termination of impulse transmission by rapid hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the central and peripheral nervous systems. The enzyme inactivation, induced by various inhibitors, leads to acetylcholine accumulation, hyperstimulation of nicotinic and muscarinic receptors, and disrupted neurotransmission. Hence, acetylcholinesterase inhibitors, interacting with the enzyme as their primary target, are applied as relevant drugs and toxins. This review presents an overview of toxicology and pharmacology of reversible and irreversible acetylcholinesterase inactivating compounds. In the case of reversible inhibitors being commonly applied in neurodegenerative disorders treatment, special attention is paid to currently approved drugs (donepezil, rivastigmine and galantamine) in the pharmacotherapy of Alzheimer's disease, and toxic carbamates used as pesticides. Subsequently, mechanism of irreversible acetylcholinesterase inhibition induced by organophosphorus compounds (insecticides and nerve agents), and their specific and nonspecific toxic effects are described, as well as irreversible inhibitors having pharmacological implementation. In addition, the pharmacological treatment of intoxication caused by organophosphates is presented, with emphasis on oxime reactivators of the inhibited enzyme activity administering as causal drugs after the poisoning. Besides, organophosphorus and carbamate insecticides can be detoxified in mammals through enzymatic hydrolysis before they reach targets in the nervous system. Carboxylesterases most effectively decompose carbamates, whereas the most successful route of organophosphates detoxification is their degradation by corresponding phosphotriesterases.
Keywords: Acetylcholine; Alzheimer’s disease drugs; acetylcholinesterase; carbamates; detoxification; irreversible inhibitors; organophosphates; reversible inhibitors..
Figures





















Similar articles
-
Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.Curr Med Chem. 2017;24(30):3283-3309. doi: 10.2174/0929867324666170705123509. Curr Med Chem. 2017. PMID: 28685687 Review.
-
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.Drugs Aging. 2004;21(7):453-78. doi: 10.2165/00002512-200421070-00004. Drugs Aging. 2004. PMID: 15132713 Review.
-
The summary on non-reactivation cholinergic properties of oxime reactivators: the interaction with muscarinic and nicotinic receptors.Arch Toxicol. 2013 Apr;87(4):711-9. doi: 10.1007/s00204-012-0977-1. Epub 2012 Nov 21. Arch Toxicol. 2013. PMID: 23179755 Review.
-
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9. Clin Pharmacokinet. 2013. PMID: 23408070 Review.
-
Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease.CNS Neurol Disord Drug Targets. 2022;21(5):427-449. doi: 10.2174/1871527320666210928160159. CNS Neurol Disord Drug Targets. 2022. PMID: 34602041 Review.
Cited by
-
Three to Tango: Inhibitory Effect of Quercetin and Apigenin on Acetylcholinesterase, Amyloid-β Aggregation and Acetylcholinesterase-Amyloid Interaction.Pharmaceutics. 2022 Oct 30;14(11):2342. doi: 10.3390/pharmaceutics14112342. Pharmaceutics. 2022. PMID: 36365159 Free PMC article.
-
Numerical Analysis and Design of an EMF Birdcage Wearable Device for the Treatment of Alzheimer's Disease: A Feasibility Study.J Biomed Sci Eng. 2022 Aug;15(8):219-227. doi: 10.4236/jbise.2022.158020. Epub 2022 Aug 17. J Biomed Sci Eng. 2022. PMID: 36032690 Free PMC article.
-
Alkaloids of Abuta panurensis Eichler: In silico and in vitro study of acetylcholinesterase inhibition, cytotoxic and immunomodulatory activities.PLoS One. 2020 Sep 29;15(9):e0239364. doi: 10.1371/journal.pone.0239364. eCollection 2020. PLoS One. 2020. PMID: 32991579 Free PMC article.
-
Evaluation of the joint toxicity of chlorpyrifos ethyl and fenobucarb on climbing perch (Anabas testudineus) from rice fields in the Mekong Delta, Vietnam.Environ Sci Pollut Res Int. 2018 May;25(14):13226-13234. doi: 10.1007/s11356-016-6980-y. Epub 2016 Jun 2. Environ Sci Pollut Res Int. 2018. PMID: 27250094
-
Ensemble machine learning to evaluate the in vivo acute oral toxicity and in vitro human acetylcholinesterase inhibitory activity of organophosphates.Arch Toxicol. 2021 Jul;95(7):2443-2457. doi: 10.1007/s00204-021-03056-6. Epub 2021 May 1. Arch Toxicol. 2021. PMID: 33934188
References
-
- Massoulie J, Pezzementi L, Bon S, Krejci E, Vallette FM. Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 1993;41(1 ):31–91. - PubMed
-
- Koelle GB. The histochemical localization of cholinesterases in the central nervous system of the rat. J. Comp. Anat. 1954;100(1 ):211–235. - PubMed
-
- Wang R, Tang XC. Neuroprotective Effects of Huperzine A. Neurosignals. 2005;14:71–82. - PubMed
-
- Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M, Bilodeau AS, Bellemare A, Cote M, Herskovits P, Touati M, Turcotte C, Valeanu L, Lemee N, Wilgus H, Begin I, Bhatia B, Rao K, Neveu N, Brochu E, Pierson J, Hockley DK, Cerasoli DM, Lenz DE, Karatzas CN, Langermann S. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl. Acad. Sci. U.S.A. 2007;104(34 ):13603–13608. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources